

Special Issue

Long-Term Immunity and Booster Strategies for COVID- 19 Vaccines

Message from the Guest Editors

This Special Issue invites original research and reviews from both basic science and clinical studies to address **the long-term dynamics of immunity to SARS-CoV-2 following vaccination and critically evaluate booster strategies for non-high-risk individuals**. Topics of interest include **immune imprinting, hybrid immunity, correlates of protection, variant-specific vaccine responses, and public health implications of risk-stratified vaccination**. By assembling this body of work, we aim to obtain useful evidence that could help building rational, individualized vaccination policies for SARS-CoV-2 for the large population of non-high-risk individuals.

Guest Editors

Dr. Alejo Erice

Department of Medicine, Hospital Asepeyo, 28823 Madrid, Spain

Prof. Dr. Ortiz De Lejarazu

National Influenza Centre, 47005 Valladolid, Spain

Deadline for manuscript submissions

31 March 2026



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/250219

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,
University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).